Previous 10 | Next 10 |
Gainers: NanoVibronix (NAOV) +106%.Carvana (CVNA) +33%.AIM ImmunoTech (AIM) +25%.GameStop (GME) +21%.Boxlight (BOXL) +20%.Rockwell Medical (RMTI) +20%.Blink Charging (BLNK) +19%.Natural Alternatives International (NAII) +18%.Issuer Direct (ISDR) +17%.Renren (RENN) +16%.Losers:&...
ADC Therapeutics (ADCT) commences public offering of 5.5M common shares.Underwriters' over-allotment is an additional 825,000 shares by certain existing shareholders. Morgan Stanley, BofA and Cowen are acting as joint book-running managers for the offering. For further details see: ADC ...
ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates for patients with hematological malignancies and solid tumors, announced today the commen...
ADC Therapeutics (ADCT) has submitted marketing application with FDA seeking approval for loncastuximab tesirine (Lonca) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)).The company says that the application is based on efficacy...
Submission based on efficacy and safety data from LOTIS 2 clinical trial ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (AD...
ADC Therapeutics (NYSE: ADCT ) has presented data interim data from an ongoing Phase 1b trial of camidanlumab tesirine (Cami, formerly ADCT-301), an anti-CD25 targeted therapy in patients with advanced solid tumors More news on: ADC Therapeutics SA, Healthcare stocks news, R...
Preliminary pharmacokinetic and biomarker data support continued evaluation of Cami as a novel immuno-oncology approach for patients with solid tumor cancers ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and c...
Preclinical study published in the Journal for ImmunoTherapy of Cancer supports continued evaluation of CD25-targeted ADC in Phase 1b clinical trial in selected advanced solid tumors ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneeri...
ADC Therapeutics SA (NYSE: ADCT), today gave notice that Morgan Stanley & Co. LLC and BofA Securities, Inc., the lead book-running managers in the Company’s recent initial public offering, are releasing a lock-up restriction with respect to 105,000 common shares held by A.T. Holdin...
ADC Therapeutics SA (ADCT) Q2 2020 Earnings Conference Call August 18, 2020, 08:30 ET Company Participants Amanda Hamilton - IR Officer Christopher Martin - CEO & Director Jay Feingold - Chief Medical Officer, Head, Oncology Clinical Development & Senior VP Jennifer Cre...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...